Merck's Diabetes Drug Meets Primary Endpoint in Key Studies - Zacks.com

Merck's Diabetes Drug Meets Primary Endpoint in Key Studies Zacks.com The two late stage studies - VERTIS MET and VERTIS SITA - evaluated the combination of ertugliflozin (5 mg and 15 mg daily) with metformin or Merck's another diabetes drug, Januvia (100 mg), respectively. Both the studies compared efficacy and safety ... and more »